10 most-read supply chain stories in June

A draft of President Donald Trump’s executive order on drug pricing piqued reader’s interest last month.

Advertisement

Here are the 10 most-read supply chain stories in June, starting with the most popular.

  1. 4 things to know about Trump’s executive order on drug pricing
  1. UPMC Health Plan launches center for value-based drug purchasing
  1. FDA approves new antibiotic for skin infections
  1. EpiPen competitor earns FDA approval: 5 things to know
  1. Hospira recall exacerbates ongoing baking soda shortage: 4 things to know
  1. Hospira recall drives 2 other drug companies to pull injectables from market
  1. 3 things to know about the Senate Health Committee’s drug price hearing
  1. 3 obstacles to managing the non-acute supply chain — and 3 ways to overcome them
  1. Baltimore’s naloxone supply dwindling as opioid overdose rates surge
  1. Companies perform better when supply pros are chiefs, not middle managers: 7 survey insights

More articles on supply chain:

New York City faces critical blood shortage
UPS’ newest delivery vehicles? Golf carts
6 drug, device recalls in June

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Supply Chain

  • Abbott has launched an updated version of its Oncodetect blood test, which helps clinicians determine whether cancer remains in patients…

  • Becker’s asked supply chain leaders: If you had an extra $1 million for your supply chain budget, where would it…

  • As hospitals redefine the role of supply chain leaders to focus on enterprise strategy, digital transformation and resilience, health systems…

Advertisement

Comments are closed.